Somatostatin receptor scintigraphy screening in advanced hepatocarcinoma: A multicenter French study

Nguyen‐Khac, Eric; Ollivier, Isabelle; Aparicio, Thomas; Moullart, V.; Hugentobler, Alexis; Lebtahi, Rachida; Lobry, Céline; Susini, Christiane; Duhamel, Christophe; Hommel, Séverine; Cadranel, J.F.; Joly, Jean Paul; Barbare, J.-C.; Tramier, B.; Dupas, Jean Louis

doi:10.4161/cbt.8.21.9737

Cited by 12 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate of octreotide scan positivity has not been studied in Asian population, while in the Western population it seems to be between 35 and 56% (Nguyen-Khac et al, 2009;Cebon et al, 2006), matching with the rate of positivity in the immunohistochemistry studies.…”

Section: Somatostatin Receptors (Ssts)mentioning

confidence: 56%

Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology

Lamarca

Mendiola²,

Barriuso

2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the third leading cause of cancer-related death. The high rate of diagnosis in non-curable stages and the lack of novel active treatments make it necessary to review all the possible sources of misleading results in this scenario. The incidence of HCC shows clear geographical variation with higher annual incidence in Asia and Africa than in Western countries; we aimed to review the literature to find if there are different trends in the main activated molecular pathways. Hyperactivation of RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signalling and epithelial to mesenchymal transition (EMT) process are more prevalent in the Western population; however, fibroblast growth factor (FGF), transforming growth factor β (TGFβ) and Notch pathways seems to be more relevant in Asian population. Whether these variations just reflect the distinct distribution of known causes of HCC or proper ethnical differences remain to be elucidated. Nevertheless, these clearly different patterns are relevant to regional or worldwide clinical trial design. If this information is neglected by sponsors and researchers the rate of failure in HCC trials will not improve.

show abstract

Section: Somatostatin Receptors (Ssts)mentioning

confidence: 56%

Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology

Lamarca

Mendiola²,

Barriuso

2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

show abstract

“…Somatostatin receptor scintigraphy with 111 indium pentetreotide (Octreoscan) has been used to screen HCC patient for SSTR2 and/or SSTR5 positivity. In two different cohort of patients including 127 and 70 patients, SSTR2 positivity was registered in 48% and 35.7% of patients, respectively [165]. These data demonstrated that at least a subgroup of patients with HCC presents SSTR2 and/or SSTR5 expression.…”

Section: Introductionmentioning

confidence: 90%

“…These data demonstrated that at least a subgroup of patients with HCC presents SSTR2 and/or SSTR5 expression. In HCC, the positivity at Octreoscan was not related with the main clinical parameters [165,166]. However, the role of SSTR expression in HCC tissues and of Octreoscan positivity in patients with HCC should be better addressed.…”

Section: Introductionmentioning

confidence: 99%

The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets

Pivonello

Martino

Negri

et al. 2014

Infect Agents Cancer

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide. Different signalling pathways have been identified to be implicated in the pathogenesis of HCC; among these, GH, IGF and somatostatin (SST) pathways have emerged as some of the major pathways implicated in the development of HCC. Physiologically, GH-IGF-SST system plays a crucial role in liver growth and development since GH induces IGF1 and IGF2 secretion and the expression of their receptors, involved in hepatocytes cell proliferation, differentiation and metabolism. On the other hand, somatostatin receptors (SSTRs) are exclusively present on the biliary tract. Importantly, the GH-IGF-SST system components have been indicated as regulators of hepatocarcinogenesis. Reduction of GH binding affinity to GH receptor, decreased serum IGF1 and increased serum IGF2 production, overexpression of IGF1 receptor, loss of function of IGF2 receptor and appearance of SSTRs are frequently observed in human HCC. In particular, recently, many studies have evaluated the correlation between increased levels of IGF1 receptors and liver diseases and the oncogenic role of IGF2 and its involvement in angiogenesis, migration and, consequently, in tumour progression. SST directly or indirectly influences tumour growth and development through the inhibition of cell proliferation and secretion and induction of apoptosis, even though SST role in hepatocarcinogenesis is still opened to argument.This review addresses the present evidences suggesting a role of the GH-IGF-SST system in the development and progression of HCC, and describes the therapeutic perspectives, based on the targeting of GH-IGF-SST system, which have been hypothesised and experimented in HCC.

show abstract

“…Antiproliferative and proapoptotic effects of SSAs have been reported in experimental models of HCC . In human HCC, immunohistochemistry (IHC) has shown variable expression of SSTR1, SSTR2 and SSTR5 from one study to another . In addition, there is limited information regarding SSTR subcellular localization.…”

Section: Introductionmentioning

confidence: 99%

“…[27][28][29][30][31][32] In human HCC, immunohistochemistry (IHC) has shown variable expression of SSTR1, SSTR2 and SSTR5 from one study to another. 28,[33][34][35][36][37] In addition, there is limited information regarding SSTR subcellular localization.…”

Section: Introductionmentioning

confidence: 99%

Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis

et al. 2016

View full text Add to dashboard Cite

show abstract

Somatostatin receptor scintigraphy screening in advanced hepatocarcinoma: A multicenter French study

Abstract: In advanced hepatocarcinoma, we report SRS uptake in 35.7% of livers and 41.2% of metastatic sites. SRS value in screening patients for somatostatin analogue treatment remains to be assessed.

Cited by 12 publications

References 0 publications

Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology

Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology

The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets

Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis

Contact Info

Product

Resources

About